Los Angeles, Sept. 3, 2015 (GLOBE NEWSWIRE) -- BioCorRx, Inc. (BICX), developer of the Start Fresh Program, a Medication-Assisted Treatment (MAT) program, announces distribution agreements to bring the Start Fresh Program into two additional wellness centers. The agreement is part of the company's continued focus to distribute its addiction treatment program to wellness centers nationally through a partnership with Myriad Medical Marketing (MMM). The new centers are Escalon Physical Medicine and Scott Medical Health Center PC. "The upcoming availability of our program at two new centers is exciting as they will be continuing our mission of greater accessibility of the Start Fresh Program throughout the country," stated COO & interim CEO, Brady Granier.
Escalon Physical Medicine is located at 1631 4th Street, Escalon, California. The center is situated in San Joaquin County, and will be the first location to offer the program in this part of California. Scott Medical Health Center is located at 2275 Swallow Hill Rd, Building 2600, Pittsburgh, Pennsylvania 15220. The Pittsburgh metropolitan area boasts a population of over 2.5M people, many of which can benefit from the Start Fresh Program.
"The team at each new location is highly qualified to be the first to bring the Start Fresh Program to more families and individuals in need of treatment in their areas. We look forward to working with them and their existing patient base, who can soon receive holistic care in the same location where they are receiving treatment on a private, out-patient basis for their addiction to alcohol or opioids," said Granier
Visit BioCorRx, Inc.'s investor relations website www.BICXcorp.com to receive the most up to date company information.
BioCorRx, Inc. ® (OTCQB: BICX) is an addiction treatment and rehabilitation company offering a unique approach to the treatment of substance abuse addiction. The Start Fresh Program®, a Medication-assisted Treatment (MAT) program, consists of two components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers therapeutic levels of the drug Naltrexone, an opioid antagonist that significantly reduces physical cravings for alcohol and opioids, into the body. The second component of the program developed by BioCorRx, Inc. is a one on one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions. Clinic reports show that the treatment program can be successful for individuals who complete the program. For more information on BICX, visit www.BioCorRx.com
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
CONTACT: Investor Relations SmallCapVoice.com, Inc. 512-267-2430